1206524-85-7

Basic information

• Product Name: MK-5172
• Synonyms: MK-5172;(1aR,5S,8S,10R,22aR)-5-(1,1-Dimethylethyl)-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-14-methoxy-3,6-dioxo-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid;8H-7,10-Methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid, 5-(1,1-diMethylethyl)-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-14-Methoxy-3,6-dioxo-,(1aR,5S,8S,10R,22aR)-;(1aR,5S,8R,10S,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid;Grazoprevir Intermediate 5;(33R,35S,91R,92R,5S)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxylicacid;(1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacy
• CAS NO: 1206524-85-7
• Molecular Formula: C₂₉H₃₈N₄O₇
• Molecular Weight: 554.63462
• EINECS: 1592732-453-0
• Product Categories: intermediates;MK-5172 intermediate
• Mol File: 1206524-85-7.mol

Chemical Properties

• Boiling Point: 824.997 °C at 760 mmHg
• Flash Point: 452.742 °C
• Appearance: /
• Density: 1.33
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• Solubility: Acetone (Slightly), Chloroform (Slightly), DMSO (Slightly, Sonicated), Methanol
• PKA: 3.23±0.40(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: MK-5172(CAS DataBase Reference)
• NIST Chemistry Reference: MK-5172(1206524-85-7)
• EPA Substance Registry System: MK-5172(1206524-85-7)

Safety Data

• Hazardous Substances Data: 1206524-85-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
MK-5172 is used as an antiviral agent for the treatment of hepatitis C virus infections. Its selective inhibition of the NS3/4A protease disrupts the virus's replication process, thereby limiting the spread of the infection and aiding in the recovery of patients.
The specific application reason for MK-5172 in the pharmaceutical industry is its ability to target the hepatitis C virus NS3/4A protease, which is crucial for the virus's replication and survival. By inhibiting this protease, MK-5172 can effectively combat the virus across different genotypes and even in cases where resistance to other treatments has developed.

Upstream product

• 1206524-84-6 methyl (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxa-diazacyclononadecino[11,12-b]quinoxaline-8-carboxylate 
• 1206524-79-9 1-(tert-butyl) 2-methyl (2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-1,2-dicarboxylate 
• 1361028-94-5 methyl (4R)-4-[(3-chloro-7-methoxyquinoxalin-2-yl)oxy]-L-prolinate hydrochloride 
• 1384277-05-7 trans 2-(pent-4-en-1-yl)cyclopropanol 
• 1026200-25-8 methyl 3-methyl-N-({[(1R,2R)-2-pent-4-en-1-ylcyclopropyl]oxy}carbonyl)-L-valinate 
• 1026200-27-0 3-methyl-N-({[(1R,2R)-2-pent-4-en-1-ylcyclopropyl]oxy}carbonyl)-L-valine 
• 1206524-81-3 (2S,4R)-methyl 4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)-1-((S)-3,3-dimethyl-2-((((1R,2R)-2-(pent-4-en-1-yl)cyclopropoxy)carbonyl)amino)butanoyl)pyrrolidine-2-carboxylate 
• 1206524-82-4 methyl 3-methyl-N-({[(1R,2R)-2-pent-4-en-1-ylcyclopropyl]oxy}carbonyl)-L-valyl-(4R)-4-[(7-methoxy-3-vinylquinoxalin-2-yl)oxy]-L-prolinate 
• 59548-39-9 4-methoxyphenylene-1,2-diamine dihydrochloride 
• 63038-27-7 L-tert-leucine methyl ester hydrochloride 
• 144164-32-9 methyl 3-methyl-N-(oxomethylene)-L-valinate 
• 124471-62-1 (E)-(hepta-1,6-dien-1-yloxy)trimethylsilane 
• 31910-18-6 2,3-dihydroxy-6-methoxyquinoxaline 
• 1425704-74-0 (R)-4-(3-{5-[(1S,2S)-2-(1-carboxy-2,2-dimethylpropylcarbamoyloxy)cyclopropyl]-1-ynyl}-7-methoxy-quinoxalin-2-yloxy)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 

Downstream Products

• 1350514-68-9 grazoprevir 

Relevant articles and documents

Synthesis of Grazoprevir, a Potent NS3/4a Protease Inhibitor for the Treatment of Hepatitis C Virus

An efficient synthesis of grazoprevir is reported. Starting from four readily available building blocks, grazoprevir is prepared in 51% overall yield and >99.9% purity for pharmaceutical use.

METHODS AND INTERMEDIATES FOR PREPARING MACROLACTAMS

The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.

Inhibitors of nedd8-activating enzyme

The invention relates to an administration unit comprising crystalline form I of {(1 S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.

Development of a practical, asymmetric synthesis of the hepatitis C virus protease inhibitor MK-5172

The development of a practical, asymmetric synthesis of the hepatitis C virus (HCV) protease inhibitor MK-5172 (1), an 18-membered macrocycle, is described.

CRYSTAL FORMS OF A HCV PROTEASE INHIBITOR

The present invention relates to different forms of a HCV inhibitory compound.

Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor

A new class of HCV NS3/4a protease inhibitors containing a P2 to P4 macrocyclic constraint was designed using a molecular modeling-derived strategy. Building on the profile of previous clinical compounds and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing. These studies led to the identification of clinical candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clinically relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.

Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors

The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.